Bijal Shah, MD @MoffittNews #ASCO22 #OncoTwitter @oncoalert ZUMA-3 Study: Two-year Follow-up

Bijal Shah, MD @MoffittNews #ASCO22 #OncoTwitter @oncoale...

2 months
18 Views
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Bijal Shah, MD, MS, is an Associate Member in the Department of Malignant Hematology at Moffitt Cancer Center. In this video, he speaks about the ASCO 2022 Abstract - Two-year follow-up of KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (Pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in ZUMA-3.

Synopsis:

The major goals of this trial are to assess the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in adults with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).